As the new CEO for Andelyn Biosciences, a Nationwide Children’s Hospital-owned gene-therapy startup, Mayo Pujols will begin to assemble a diverse team of up to 200 scientists, biochemists, engineers and technicians.
The portfolio of gene-therapy products to be manufactured at its 100,000 square-foot building on Ohio State University’s West Campus could one day become treatments for muscular dystrophy, hemophilia, neurological disorders, or heart and eye diseases.
Click here to read the complete story.
Story excerpt provided by The Columbus Dispatch.
Written by Dean Narciso.
Originally published May 1, 2020.